Allogene Therapeutics, Inc.
NASDAQ: ALLO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David D. Chang
- Employees
- 226
- Headquarters
- South San Francisco, United States
- IPO year
- 2018
- Market cap
- $499.9M
- Website
- https://www.allogene.com
Loading ALLO…
Loading profile data…Frequently asked questions about ALLO
What does Allogene Therapeutics, Inc. (ALLO) do?
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This ca...
Where does ALLO trade?
Allogene Therapeutics, Inc. (ALLO) trades on the NASDAQ Global Select.
What sector is ALLO in?
Allogene Therapeutics, Inc. (ALLO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Allogene Therapeutics, Inc.?
David D. Chang is the chief executive officer of Allogene Therapeutics, Inc. (ALLO).
Where is Allogene Therapeutics, Inc. headquartered?
Allogene Therapeutics, Inc. is headquartered in United States.
Does ALLO pay a dividend?
Allogene Therapeutics, Inc. (ALLO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALLO go public?
Allogene Therapeutics, Inc. (ALLO) completed its initial public offering in 2018.